id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-N-3326-0013,FDA,FDA-2015-N-3326,Biosimilar User Fee Act; Public Meeting; Correction,Notice,Correction,2016-09-29T04:00:00Z,2016,9,2016-09-29T04:00:00Z,,2016-09-29T15:10:02Z,2016-23523,0,0,090000648227f730
FDA-2015-N-3326-0012,FDA,FDA-2015-N-3326,Biosimilar User Fee Act; Public Meeting,Notice,Public Meetings,2016-09-19T04:00:00Z,2016,9,2016-09-19T04:00:00Z,2016-10-29T03:59:59Z,2016-10-29T01:02:33Z,2016-22442,0,0,09000064822261f0
FDA-2015-N-3326-0003,FDA,FDA-2015-N-3326,Testimony from Sandoz,Other,Testimony,2016-01-13T05:00:00Z,2016,1,2016-01-13T05:00:00Z,,2016-01-13T17:07:00Z,,0,0,0900006481e04e75